Introduction
One of the most widely investigated gene in partial epilepsy is the leucine-rich glioma-inactivated 1 (LGI1) gene. Partial epilepsy with autosomal dominant inheritance and semiological features consistent with lateral temporal lobe seizure has been reported as autosomal dominant lateral temporal lobe epilepsy (ADLTE) or autosomal dominant partial epilepsy with auditory features. The gene of ADLTE was localized to the long arm of chromosome 10 in 1995, and epilepsy related LGI1 mutation was discovered in 2002. 1, 2 In relatively small series, LGI1 mutations have been found in about 50% of ADLTE families. [3] [4] [5] On the other hand, a collaborative study of the Commission of Genetics of the Italian League Against Epilepsy reported that LGI1 mutations were found only in 10 (30%) of 33 ADLTE families. Also, they demonstrated a significantly lower penetrance rate and relative disease risk in non-
LGI1-mutated families compared with LGI1-mutated pedigrees, suggesting that a complex inheritance pattern may underlie a proportion of these families. 6 Sporadic lateral temporal lobe epilepsy cases with ictal auditory manifestations have been described as idiopathic partial epilepsy with auditory features (IPEAF). De novo LGI1 mutations have also been identified in IPEAF, and account for about 2% of sporadic cases with IPEAF. 7, 8 Twentysix LGI1 point mutations related to epilepsy have been reported to date. 9 Microdeletion of LGI1 was found in 2012. Purpose: A new leucine-rich glioma-inactivated 1 gene (LGI1) mutation inducing an amino acid sequence substitution was found in a Korean family with autosomal dominant lateral temporal lobe epilepsy (ADLTE). We report the clinical features and characteristics of this newly identified LGI1 mutation. Methods: Clinical data were collected from a large ADLTE family. All exons and flanking regions of the LGI1 gene were directly sequenced. 243 healthy controls were screened for the putative mutation. The 'Sorting Tolerant From Intolerant' algorithm was employed for the prediction of mutated LGI1 protein stability.
LGI1 protein secretion was confirmed in vitro by immunoblotting assay.
Results:
The main clinical characteristics included a young age at onset (mean, 12.4 years), diverse phenotypic manifestations, the occurrence of generalized tonic-clonic seizures, and a favorable prognosis. The genetic analysis detected a nonsynonymous single nucleotide polymorphism of c.137G > T coding for p.C46F in the five affected family members. This variant was not found in the normal control population and one unaffected family member. All the amino acids substituted for cysteine at position 46 of the LGI1 protein were predicted to damage protein stability in in silico analysis. Mutated C46F protein was retained within the cell at the immunoblotting assay.
Conclusion:
We identified a new LGI1 mutation in a large Korean ADLTE family which appeared to be involved in the development of epilepsy through suppressing LGI1 protein secretion. ß 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Recently we have encountered a Korean ADLTE family, and identified a new LGI1 mutation. We report the phenotypes, genetic features, and laboratory findings.
Methods

Subjects and data collection
A large Korean family comprising 52 members (excluding their spouses) came to our attention by simultaneously encountering affected family members in the epilepsy clinic of Severance Hospital. Detailed history taking revealed autosomal dominant inheritance of epilepsy within this family. After the approval of the Institutional Review Board of our institution, six family members [five affected members (III-15, IV-8, IV-9, IV-14, and IV-16), and one healthy member (IV-18)] who signed informed consents were interviewed and underwent genetic analysis. Data collection was focused on seizure semiology, age at seizure onset, and treatment outcomes. The routine scalp EEG recordings were available in six patients. Brain magnetic resonance imagings (MRIs) were reviewed.
Genetic analysis
We performed exon scanning of all LGI1 (NG_011832.1 from NCBI database) coding exons and splice junction sites by direct sequencing to identify variants in six family members. Additionally, any putative mutation was screened in 243 Korean population data from our database. Genomic DNA was extracted from the peripheral whole blood using a nucleic acid isolation device, QuickGene-mini80 (Fujifilm, Japan). The PCR protocol has been optimized for amplifying LGI1 based on UCSC In-Silico PCR (http:// genome.ucsc.edu/cgi-bin/hgPcr?command=start). The PCR products were purified using a MultiScreen384-PCR Filter Plate (Milipore, USA). The purified products were then sequenced using a BigDye Terminator Cycle Sequencing Kit and an ABI 3730xl automated sequencer (Applied Biosystems, USA). Mutation analyses were performed using Phred, Phrap, Consed, Polyphred 5.04 software (http://droog.mbt.washington.edu/PolyPhred.html).
Gene cloning
Coding sequence of the LGI1 gene with Xho I and EcoR I enzyme sites was obtained from the LGI1 gene in the pBluescriptR vector (Cat no. IRATp970G0723D, Image ID 4811956, Imagenes GmbH, Germany) using PCR method (forward primer: 5 0 -CCGCTCGAGGC-CACCATGGAATCAGAAAGAAGC-3 0 , reverse primer: 5 0 -GGAATTCT-CATGCGCTTAAGTCAAC-3 0 ), and inserted into the pcDNA3.1(-) vector. After that, site-directed mutagenesis PCR was performed to make the C46R and C46F mutagenized LGI1 clones (forward primer for C46R: 5 0 -CAAAATGCCCTGCCGTGCGTACTTGTACCAAAGAT-3 0 , reverse primer for C46R: 5 0 -ATCTTTGGTACAAGTACGCACGG-CAGGGCATTTTG-3 0 , forward primer for C46F: 5 0 -CCAAAATGCC-CTGCCGTGTTTACTTGTACCAAAGATAAT-3 0 , reverse primer for C46F: 5 0 -ATTATCTTTGGTATAAGTAAACACGGCAGGGCATTTTGG-3 0 , and these primers were PAGE purified).
Immunoblotting
Wild type, C46R, and C46F of LGI1 clone and pcDNA3.1(-) were transfected into the Human Embryonic Kidney (HEK) 293T cells at 6-well plate using Lipofectamine TM and Plus TM reagents (Cat no.
18324-020 and 10964-021, respectively, Invitrogen, USA), and the transfecting solution was replaced with serum free media for terminating transfection. 40 h after transfection, serum free media was separately collected and centrifuged. The supernatant was collected into the Amicon 1 Ultra-4 3K Centrifugal Filters (Cat. no. UFC800324, Millipore, USA) and centrifuged. The remaining concentrated serum free media was added with 2Â lysis buffer (40 mM Tris, 300 mM NaCl, 20% Glycerol, 2% NP-40, and protease inhibitor cocktail). Cell was washed twice with 1Â phosphate buffered saline and collected with rubber scraper at the 1Â lysis buffer (20 mM Tris, 150 mM NaCl, 10% Glycerol, 1% NP-40, and protease inhibitor cocktail), then sonicated for 15 s. Cell lysate was centrifuged and the supernatant was collected. 2Â Tricine sample buffer (Cat. no. KTR020, Koma Biotech Inc, Korea) was added to the prepared media and cell lysate. EzWay PAG System Precast Gel (4-12%) and Tricine running buffer (Cat. no. KG50105 and KTR030, respectively, Koma Biotech Inc.) were used for gel electrophoresis. Anti LGI1 (C-19) and Actin (I-19) antibodies (Cat. no. sc-9583 and sc-1616, respectively, Santa Cruz, USA) were employed as primary antibodies, and ImmunopureR antibody Rabbit anti-Goat IgG (H + L) (Cat. no. 31402, Thermo Scientific, USA) was used as a secondary antibody. Actin beta was used as a control for the cell lysate.
In silico analysis
Model for leucine-rich repeat (LRR) domain of LGI1 was calculated using automated modeling mode in the SWISS model server (http://swissmodel.expasy.org/). Two crystal structures in the LRR family of VLRB61 and Slit with four LRRs as template models were adopted for modeling process. Model figures were prepared using programs PyMol (DeLano Scientific). The amino acid substituting effect for LGI1 protein stability was predicted using the 'Sorting Tolerant From Intolerant' (SIFT) algorithm at the online tool of http://sift.jcvi.org. 
Results
Clinical description
None of family members had the information for seizure history of the first generation. Among all family members, eleven members experienced seizures: two of four in the second generation, two of 17 in the third generation, six of 11 in the fourth generation, and one of 19 in the fifth generation (Fig. 1A) . None of them had antecedents for seizure. Three of the family members were deceased (II-2, II-3, and III-12), and out of the eight who were still alive, six (III-15, IV-8, IV-9, IV-14, IV-16, and IV-19) were taking antiepileptic drugs (AEDs). The mean age at seizure onset for the eight living members was 13.6 years (range, 10 to 22 years). The current mean age of unaffected (n = 8) offspring of the affected fourth generation (IV-11, IV-14, and IV-16) is 13.1 years (range, 7-18 years). All affected family members were righthanded. The three deceased members had generalized tonic-clonic seizures (GTCSs), and no living family member remembered the characteristics of deceased members' auras. All living affected members had GTCSs. Patients IV-11 and V-9 had only one GTCS in their lifetime. GTCSs occurred predominantly during sleep in four members (III-15, IV-8, IV-16, and IV-19). Four members (III-15, IV-9, IV-14, and IV-16) had complex partial seizures (CPSs). Two members (III-15 and IV-14) described specific seizure precipitants such as psychic stress, speech, and visual stimulus. The auras of seven living members were as follows: simple or complex auditory hallucinations (IV-8 and IV-9), vertiginous auras (IV-8, IV-16 and IV-19), complex visual hallucinations (III-15), and psychic auras (IV-14 and V-9). Six patients (III-15, IV-8, IV-9, IV-14, IV-16, and IV-19) underwent routine scalp EEG recording with nasopharyngeal electrodes. One patient (IV-16) showed synchronous bilateral temporal sharp waves. Brain MRIs of five patients (III-15, IV-8, IV-14, IV-16, and IV-19) revealed no significant findings. Seizure outcomes were favorable. Six of the eight family members (III-15, IV-9, IV-11, IV-16, IV-19, and V-9) had been seizure-free for !1 year before the time of the last follow-up. Patient IV-11 was never treated with AED. Patient V-9 was treated with AEDs for three years but was able to discontinue medication. Two patients (IV-8 and IV-14) receiving AEDs were still experiencing seizures. Clinical profiles are summarized in Table 1 .
Gene analysis
One nucleotide variant, c.137G > T was shared within the five affected members, and this variant was not detected at the unaffected member and healthy controls. Each affected subject had only one c.137G > T variant allele (Fig. 1B) . All tested affected members had heterozygote amino acid of p.C46F encoded by the c.137G > T. which is located next to the c.136T > C coding p.C46R known as rs104894166. C46R variant was already reported at the members of Norwegian family. 12 
Protein secretion
Wild type LGI1 protein was detected in both cell lysate and media. C46R and C46F mutation was only detected in the cell lysate (Fig. 1C) . 
Protein structure and stability
There is a LRR domain at the center of the two cysteine rich domains (Fig. 1D) . Each cysteine rich domain has two disulfide bonds composed of four cysteine residues. Of the two disulfide bonds existed in the cysteine rich domain N-terminal to LRR, one is located between the C42 and C48, and the other is between the C46 and C55. In the case of the C46F mutation, two disulfide bonds in the cysteine rich domain C-terminal to LRR are declined to one.
LGI1 protein stability was predicted as 'Tolerated' or 'Damaging' according to the amino acid substitution for C46. All amino acids substituted for cysteine were predicted as 'Damaging' status using SIFT algorithm. Results of in silico analysis are shown in the on-line supplementary data.
Discussion
The LGI1 protein has two main structural domains; four LRRs in the N-terminal half, and seven epitempin (EPTP) repeats in the Cterminal portion. 13 Three LGI1 mutations affecting conserved cysteine residue preceding LRR were reported to date. 3, 5, 14 Disulfide bonds formed by cysteine residues play an important role in maintaining structural stability by protecting the LRR hydrophobic core from exposure. 15 Although in silico analysis using SIFT algorithm has a limitation for predicting the effect of amino acid substitution that it does not use the protein structure, all amino acids substituted at the C46 position impaired the protein stability on SIFT prediction. 11 Most epilepsy-associated mutant LGI1 proteins were retained within the cell except for the one encoded by the mutation (c.1219C > T). 9 The C46F protein was also retained within the cell in our experiment. These findings reemphasize that conserved cysteine residue is a critical region for normal protein function and a single functioning copy of LGI1 gene is not enough for normal function, so that loss-of-function mutations cause a dominant phenotype in this family. The putative function of LGI1 protein is still unclear. The LGI1 protein has been found associated with different protein complexes and several molecular mechanisms possibly underlying ADLTE have been hypothesized. LGI1 forms membrane complexes with Kv1.1 potassium channels. Both Kv1.1 and LGI1 are coassembled with KV1.4 and Kvbeta1.
LGI1 selectively prevents N-type inactivation mediated by the Kvbeta subunit. Changes in inactivation gating of presynaptic Kv1.1 potassium channels may promote epileptic activity. 16 Extracellularly secreted LGI1 links two epilepsy-related receptors, ADAM22 and ADAM23, in the brain and organizes a transsynaptic protein complex that includes presynaptic potassium channels and postsynaptic AMPA receptor scaffolds. A lack of LGI1 disrupts this synaptic protein connection and selectively reduces AMPA receptor-mediated synaptic transmission. 17 Also, LGI1 binding to ADAM23 is necessary to correctly pattern neuronal morphology and altered anatomical patterning contributes to ADLTE. 18 Clinical findings were generally consistent with the characteristics of ADLTE. Focal seizures are clinically characterized by auditory auras in the majority of the cases. Other less frequent auras include aphasic, visual, psychic, autonomic, vertiginous, and other sensory symptoms. 19 Two families with the C46R mutation had prominent aphasic or auditory auras. 12, 14 The auras of our patients appeared to be more diverse compared to the auras induced by the C46R mutation. Five patients had psychic, dizziness, and visual auras. Only two patients had auditory auras. Ictal aphasia may not have been identified because of the lack of prolonged EEG monitoring. Secondarily GTCSs are almost invariably present in patients with ADLTE which is consistent with our results. 4 Seizures could be triggered by sounds, speech, or others factors in ADLTE. One patient with visual auras described visual stimuli as one of her seizure precipitants. The precipitating triggers may reflect the natural function of epileptogenic focus in reflex seizure. The progression of the condition is usually benign. Six of eight living family members achieved seizure freedom. In the fifth generation (n = 11) whose parent had seizures, only one member (V-9) experienced seizures. The paucity of seizure in the fifth generation may be explained by still low age for seizure onset or incomplete penetrance (67% and 61.3%, respectively, in two studies).
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Conclusions
A new LGI1 mutation was identified in a large Korean ADLTE family. Sequencing of LGI1 revealed a heterozygous G to T transversion at position 137 of the cDNA resulting in a missense mutation in exon 1, which is predicted to substitute phenylalanine for cysteine at position 46 of the LGI1 protein (C46F). Clinical and genetic features were generally consistent with the previously reported cases with the exception of the diversity of auras among the affected family members. Further studies are required to evaluate the phenotypic diversities of LGI1 mutation related ADLTE.
